Effective Target Identification

Although there are hundreds of essential bacterial proteins, most are not good drug targets. Using structural bioinformatics, the Trius team carefully selects protein targets possessing conserved active site architectures across important pathogenic bacterial species. In addition, Trius has developed a broadly applicable bacterial antisense technology that sensitizes the bacteria to inhibition of any protein target of our choosing. Taken together, these approaches validate our protein targets as candidates for chemotherapy, allow us to choose targets that maximize the potential spectrum of our antimicrobial agents, and insure that our inhibitors are on target.